Europe Meningococcal Vaccine Market By Brand (Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands), By Type (Bivalent, Quadrivalent and Other Types), By Age Group (Infants (0 to 2 years) and Children (2 years & above)), By Country, Industry Analysis and Forecast, 2020 - 2026

Analysis of Market Size & Trends

The Europe Meningococcal Vaccine Market would witness market growth of 8% CAGR during the forecast period (2020-2026). Meningococcal vaccines are perceiving a significant demand in line with a prominent increase in routine immunization. Increasing use of meningococcal vaccines for immunizing special risk groups, such as travellers, or military personnel is fueling gains in the market.

Moreover, non-profit organizations offering funds for research projects, healthcare professionals training, and providing information & support to patients. All these factors are anticipated to propel market growth. For example, the Meningitis Research Foundation has approved 161 research grants and invested about USD 28.0 million for scientific researches. Through this organization, people and expertise come together in order to face challenges in preventing meningitis.

In addition to it, the phase III vaccines in trials that are expected to be commercialized over the projected period, are anticipated to drive the market growth. For example, MenACYW, which is a conjugate vaccine manufactured by Sanofi, is in phase III clinical trial.

There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.

Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: Meningococcal Vaccine Market in Europe is expected to register a CAGR of 8% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

Scope of the Study

Market Segments Covered in the Report:

By Brand

• Bexsero
• Trumenba
• Nimenrix
• Menactra
• Menveo
• Other Brands

By Type

• Bivalent
• Quadrivalent
• Other Types

By Age Group

• Infants (0 to 2 years)
• Children (2 years & above)

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Pfizer, Inc.
• Sanofi S.A.
• Walvax Biotechnology Co., Ltd.
• Bio-Manguinhos (Oswaldo Cruz Foundation)
• Bio-Med Pvt. Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.
• Hualan Biological Engineering, Inc.
• Incepta Pharmaceuticals Ltd.
• Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)